Death versus dedifferentiation: The molecular bases of beta cell mass reduction in type 2 diabetes.

  title={Death versus dedifferentiation: The molecular bases of beta cell mass reduction in type 2 diabetes.},
  author={Tong Sun and Xiao Han},
  journal={Seminars in cell \& developmental biology},
  • Tong Sun, Xiao Han
  • Published 2019
  • Medicine, Biology
  • Seminars in cell & developmental biology
Diabetes Mellitus is currently affecting more than 425 million people worldwide, among which over 90 % of the cases belong to type 2 diabetes. The number is growing quickly every year. Together with its many complications, the disease is causing tremendous social and economic burden and is classified as one of the leading causes of high morbidity and mortality rate. Residing in the islets of Langerhans, pancreatic beta cell serves as a central mediator in glucose homeostasis through secreting… Expand
A Brief Review of the Mechanisms of β-Cell Dedifferentiation in Type 2 Diabetes
A better understanding of β- cell dedifferentiation process will help to identify novel therapeutic targets to prevent and/or reverse β-cell loss in type 2 diabetes. Expand
MicroRNA Sequences Modulated by Beta Cell Lipid Metabolism: Implications for Type 2 Diabetes Mellitus
This review sought to identify the microRNA sequences regulated by metabolic challenges in beta cells and islets, their targets, highlight their function and assess their possible relevance as biomarkers of disease progression in diabetic individuals. Expand
A direct look at the dysfunction and pathology of the β cells in human type 2 diabetes.
This review focuses on several features of human β cell dysfunction and pathology in type 2 diabetes, as revealed by direct assessment of isolated islet traits and examination of pancreatic tissue from organ donors, surgical samples or autoptic specimens. Expand
The Plasticity of Pancreatic β-Cells
Novel treatment(s) for diabetes targeting islet cell plasticity is outlined, such as transdifferentiation of pancreatic β-cell to α-cell and vice versa, because islet cells can exhibit plasticity, and they may have the ability to redifferentiate into any cell type. Expand
Targeting β-cell dedifferentiation and transdifferentiation: opportunities and challenges
It is explored the possibility that there might be a time interval from the onset of β-cell dysfunction caused by dedifferentiation to the development of diabetes, which may offer a therapeutic window to reduce β- cell injury and to stabilize functionality. Expand
Long Non-Coding RNAs as Key Modulators of Pancreatic β-Cell Mass and Function
An overview of the roles of lncRNAs in maintaining β-function and mass is provided, and their relevance in the development of diabetes is discussed. Expand
Relationship Between Insulin-Receptor Substrate 1 and Langerhans’ Islet in a Rat Model of Type 2 Diabetes Mellitus
The reduction of IRS1 was weakly correlated with the destruction of Langerhans’ islets, suggesting there is an intermediate step between both parameters. Expand
NGBR is required to ameliorate type 2 diabetes in mice by enhancing insulin sensitivity
  • Yi Chen, Wenquan Hu, +11 authors Yajun Duan
  • Medicine
  • The Journal of biological chemistry
  • 2021
It is demonstrated that NGBR expression was decreased in the liver of obesity-associated T2D patients and db/db mice, providing new insight into the role of hepatic N GBR in insulin sensitivity and T1D treatment. Expand
Elevated 4-hydroxynonenal induces hyperglycaemia via Aldh3a1 loss in zebrafish and associates with diabetes progression in humans
Increased methylglyoxal (MG) formation is associated with diabetes and its complications. In zebrafish, knockout of the main MG detoxifying system Glyoxalase 1, led to limited MG elevation butExpand
Evaluation of Pharmacokinetic Properties, Toxicity, and Bioactive Cytotoxic Activity of Black Rice (Oryza sativa L.) as Candidates for Diabetes Mellitus Drugs by in silico
The in silico method is widely used to search for drug candidates, namely by predicting physicochemical properties, pharmacokinetics (ADME), toxicity, know the description of drug interactions withExpand


Pancreatic β Cell Mass Death
Evidence that β cell development and mass formation are guided by specific signaling systems, particularly hormones, transcription factors, and growth factors, all of which could be manipulated to enhance mass growth is discussed. Expand
Evidence of β-Cell Dedifferentiation in Human Type 2 Diabetes.
The data support the view that pancreatic β-cells become dedifferentiated and convert to α- and δ-"like" cells in human type 2 diabetes, and should prompt a reassessment of goals in the prevention and treatment of β-cell dysfunction. Expand
Beta‐Cell Dedifferentiation in Type 2 Diabetes: Concise Review
This study evaluated the evidence for β‐cell dedifferentiation in T2D, and T1D and examined experimental systems in which its mechanisms may be studied and concluded that prevention or induction of cell redifferentiation is needed for restoration of the functional β‐ cell mass. Expand
Pancreatic β cell dedifferentiation in diabetes and redifferentiation following insulin therapy.
It is demonstrated here that β cell dedifferentiation, rather than apoptosis, is the main mechanism of loss of insulin-positive cells, and redifferentiation accounts for restoration of insulin content and antidiabetic drug responsivity in these animals. Expand
Apoptosis in pancreatic β-islet cells in Type 2 diabetes.
  • T. Tomita
  • Medicine
  • Bosnian journal of basic medical sciences
  • 2016
Animal models using knockout mice will shed light on the basic understanding of the pathophysiology of diabetes as a glucose metabolic disease complex, on the balance of anti-apoptotic Bcl family and pro-APoptotic genes, and will lead to eventual prevention and therapeutic application for T2DM with improving medications. Expand
High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program.
Comparing the effect of 5 days' culture in high glucose concentration versus normal glucose levels or hyperosmolar control on the survival of human pancreatic islets suggests that in human islets, high glucose may modulate the balance of proapoptotic and antiap optotic Bcl proteins toward apoptosis, thus favoring beta-cell death. Expand
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Since the major defect leading to a decrease in beta-cell mass in type 2 diabetes is increased apoptosis, while new islet formation and Beta-cell replication are normal, therapeutic approaches designed to arrest apoptosis could be a significant new development in the management of type 1 diabetes. Expand
β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.
  • Y. Saisho
  • Medicine
  • World journal of diabetes
  • 2015
Reducing β-cell workload appears to be the most effective way to preserve β- cell functional mass to date, underpinning the importance of lifestyle modification and weight loss for the treatment and prevention of T2DM. Expand
Mechanisms of β-cell dedifferentiation in diabetes: recent findings and future research directions.
The role of Foxo1, Myc and inhibitor of differentiation proteins are discussed, the emerging role of non-coding RNAs are highlighted and a novel hypothesis of β-cell dedifferentiation as a potential adaptive mechanism to escape cell death under stress conditions is proposed. Expand
&bgr;-Cell Dedifferentiation in Patients With T2D With Adequate Glucose Control and Nondiabetic Chronic Pancreatitis
The data support the view that pancreatic β-cells are dedifferentiated in patients with T2D with adequate glucose control and suggest that inflammation-induced β-cell dedifferentiation can be a cause of pancreatogenic diabetes during disease progress. Expand